Archives

ISA106’s promising results in preclinical tests warrant fast entry into human studies to address the need for effective COVID-19 therapy

March 3rd, 2021 – ISA announces that it has completed pre-clinical work for ISA106, a novel COVID-19 immunotherapy and is planning clinical trials. A phase 1 dose finding study in healthy volunteers will start in the next few months.

ISA106 is an immunotherapy agent that is intended to treat patients with SARS-CoV2 infections, and prevent progressive pneumonia and further complications – thereby avoiding admission to hospital and ICU. It is designed to elicit a robust T cell immune response specifically against SARS-CoV2,